BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1624541)

  • 1. The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma.
    Schirner M; Schneider MR
    J Cancer Res Clin Oncol; 1992; 118(7):497-501. PubMed ID: 1624541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma.
    Schirner M; Lichtner RB; Schneider MR
    Clin Exp Metastasis; 1994 Jan; 12(1):24-30. PubMed ID: 8287616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cicaprost inhibits metastases of animal tumors.
    Schirner M; Schneider MR
    Prostaglandins; 1991 Nov; 42(5):451-61. PubMed ID: 1763201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors.
    Schneider MR; Schirner M; Lichtner RB; Graf H
    Breast Cancer Res Treat; 1996; 38(1):133-41. PubMed ID: 8825130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rodent model of systemic mammary tumor disease by surgical removal of the spontaneously metastasizing SMT2A mammary carcinoma: inhibitory effect of the stable prostacyclin analogue cicaprost on occult metastasis.
    Schirner M; Schneider MR
    Int J Cancer; 1995 Jul; 62(2):205-9. PubMed ID: 7622297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth.
    Schirner M; Schneider MR
    Cancer Detect Prev; 1997; 21(1):44-50. PubMed ID: 9043762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor metastasis inhibition with the prostacyclin analogue cicaprost depends on discontinuous plasma peak levels.
    Schirner M; Kraus C; Lichtner RB; Schneider MR; Hildebrand M
    Prostaglandins Leukot Essent Fatty Acids; 1998 Apr; 58(4):311-7. PubMed ID: 9654405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prostacyclin analogues in in vivo tumor models.
    Schneider MR; Schillinger E; Schirner M; Skuballa W; Stürzebecher S; Witt W
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():901-8. PubMed ID: 1705084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin and its analogues: antimetastatic effects and mechanisms of action.
    Schneider MR; Tang DG; Schirner M; Honn KV
    Cancer Metastasis Rev; 1994 Dec; 13(3-4):349-64. PubMed ID: 7712596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Cicaprost on metastasis in advanced tumor disease.
    Schirner M; Lichtner RB; Graf H; Schneider MR
    Adv Exp Med Biol; 1997; 400B():751-6. PubMed ID: 9547626
    [No Abstract]   [Full Text] [Related]  

  • 11. Cicaprost does not affect tumor inhibitory potential of cytostatic drugs.
    Schirner M; Schneider M
    Anticancer Res; 1993; 13(3):743-6. PubMed ID: 8317906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 3H-cicaprost in healthy volunteers.
    Hildebrand M; Staks T; Schütt A; Matthes H
    Prostaglandins; 1989 Feb; 37(2):259-73. PubMed ID: 2657866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and properties of cell lines from the metastasising rat mammary tumour SMT-2A.
    Rudland PS; Dunnington DJ; Kim U; Gusterson BA; O'Hare MJ; Monaghan P
    Br J Cancer; 1989 Jun; 59(6):854-64. PubMed ID: 2736223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.
    Qian YM; Jones RL
    Br J Pharmacol; 1995 May; 115(1):163-71. PubMed ID: 7544196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganglioside profiles of metastases and of metastasizing and nonmetastasizing rat primary mammary carcinomas.
    Skipski VP; Carter SP; Terebus-Kekish OI; Podlaski FJ; Peterson RH; Stock CC
    J Natl Cancer Inst; 1981 Dec; 67(6):1251-8. PubMed ID: 6947108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of the metastatic potential of three transplantable rat mammary carcinomas of spontaneous origin.
    Willmott N; Austin EB; Baldwin RW
    Br J Exp Pathol; 1979 Oct; 60(5):499-506. PubMed ID: 518819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanisms of enhancement and inhibition of field stimulation responses of guinea-pig vas deferens by prostacyclin analogues.
    Tam FS; Chan K; Borreau JP; Jones RL
    Br J Pharmacol; 1997 Aug; 121(7):1413-21. PubMed ID: 9257922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between lymphogenous and hematogenous metastasis in rats bearing the MT-100-TC mammary carcinoma.
    Ward PM; Weiss L
    Clin Exp Metastasis; 1989; 7(3):253-64. PubMed ID: 2924446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.